Q32 Bio raises $10.5M in registered direct offering to fund bempikibart trials

Q32 Bio Inc.

Gross proceeds of ~$10.5M from 1,666,679 common shares and pre-funded warrants for 1,025,654 shares at $3.90/share.
Offering price equals Feb 13 closing price; pre-funded warrants exercisable at $0.0001/share.
Net proceeds for working capital, including advancing bempikibart for alopecia areata into future trials.
Closing expected Feb 18, 2026; led by new institutional investor with participation from existing investor.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Q32 Bio Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $10.5 million (effective 2026-02-17).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: approximately $10.5 million
Effective: 2026-02-17

Exact text from the filing

On February 17, 2026, Q32 Bio Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors relating to the issuance and sale of (i) 1,666,679 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $3.90 per share, and (ii) pre-funded warrants to purchase 1,025,654 shares of Common Stock (the “Pre-Funded Warrants”), to such investors in a registered direct offering (the “Offering”).

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Q32 Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-054711

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.